• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Immunomedics to present CEA-Scan data

Article

Monoclonal antibody imaging agent developer Immunomedics of MorrisPlains, NJ, said this month that the Food and Drug Administrationhas scheduled a date for the company to present data from clinicaltrials for its CEA-Scan colorectal cancer imaging agent.

Monoclonal antibody imaging agent developer Immunomedics of MorrisPlains, NJ, said this month that the Food and Drug Administrationhas scheduled a date for the company to present data from clinicaltrials for its CEA-Scan colorectal cancer imaging agent. The moveis a follow-up to an action last year in which the FDA said CEA-Scan'sproduct license application was not approvable in its form atthe time (SCAN 6/1/94).

The FDA has scheduled the meeting for Oct. 17, at which timethe two parties will discuss the FDA's request for clarificationof the data and analyses Immunomedics provided the agency in responseto the not-approvable letter. The regulatory status of CEA-Scan'sPLA for colorectal cancer imaging is not-yet-approvable, accordingto Immunomedics.

In other Immunomedics news, the company reported progress onseveral other agents it is developing. It said last week thatphase-III clinical trials for its LeukoScan infectious diseaseimaging agent have demonstrated clear diagnostic utility for imagingbone infections. Other trials have supported the use of CEA-Scanin breast cancer imaging.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.